Public datasets have shown that high levels of CD137hiIFNγhi CD8+ T cells are linked to a high response rate, suggesting CD137 may be a potential biomarker for predicting the effectiveness of cancer immunotherapy [44,45,46]. The gene discussed is CD8A; the disease is cancer.